- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03019913
Evaluation of Bedside Methods to Measure Muscularity in Critically Ill Patients
Evaluation of Bedside Methods to Measure Muscularity in Critically Ill Patients: A Prospective Observational Study
Muscle wasting is a significant problem in critically ill patients, with reported losses of a half to three percent per day over the first ten days (for an average 70kg person this equates to 3 to 20kg of muscle loss). Low skeletal muscle mass at admission to the intensive care unit (ICU) and the loss of lean tissue have been associated with negative clinical outcomes, including increased incidence of infections, length of stay, mortality and muscle weakness. It is therefore crucial that technology is utilised to: 1) identify ICU patients with low muscularity on admission, 2) to help understand the factors impacting muscle loss and to 3) assess the effectiveness of interventions aimed at maintaining skeletal muscle mass in this population.
The measurement of lean body mass in patients admitted to the ICU is challenging however, due to the large fluid shifts that occur in this population and logistical issues in moving patients to specialised machinery for body composition analysis. Currently, there is no validated method for accurately assessing a patient's muscle mass at the bedside in the intensive care setting. It is therefore important to investigate the accuracy, feasibility and reliability of bedside methods such as subjective physical assessment of muscle mass, mid arm muscle circumference, ultrasound and bioimpedance analysis to assess muscularity in this population who are primarily bedbound. In order to do this, a critical comparison is required between these methods and muscularity assessed by a "reference" body composition method, such computed tomography (CT) image analysis. Briefly, quantification of skeletal muscle at the abdomen area utilising abdominal CT images has been shown to be highly representative of whole body skeletal muscle volume.
We wish to conduct a pilot, feasibility study (n= 50), which will recruit patients who have a CT scan (containing abdomen area), performed for clinical purposes. Our primary aim will be to investigate whether muscularity assessed with non-invasive bedside methods (ultrasound, bioimpedance analysis, SGA physical assessment, mid arm muscle circumference) are correlated with skeletal muscle mass quantified by a "reference method" (CT image analysis).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Aim Our primary aim is to investigate whether muscularity assessed via bedside ultrasound is correlated with a reference method for estimating whole body skeletal muscle mass (CT image analysis) in the first few days of critical illness.
Our secondary aims are
- To investigate whether muscularity assessed via other bedside methods (bioimpedance spectroscopy, subjective physical assessment and mid arm muscle circumference) are correlated with a reference method for estimating whole body skeletal muscle mass (CT image analysis) in critically ill patients.
- To better understand the association between measured resting energy expenditure and muscularity in the critically ill.
- To observe changes in skeletal muscle mass (in a sub set of patients who have two CT scans) and the impact various factors, including energy and protein delivery has on these changes.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- The Alfred Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Have had a CT scan of the L3 vertebra performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
Exclusion Criteria:
- CT scan performed >48hrs ago
- Death is imminent or deemed highly likely in the next 96 hours
- Are known to be pregnant
- Treating clinician does not believe the study to be in the best interest of the patient
- It is not possible to image two or more muscle groups via ultrasound (i.e. due to trauma, burns, wounds)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Mean skeletal muscle mass measured by CT scan analysis at L3 area (cm2)
Periodo de tiempo: CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
|
Mean skeletal muscle mass measured by ultrasound (muscle thickness at each site, cm and rectus femoris CSA, cm2)
Periodo de tiempo: <48 hours after CT scan containing L3 area
|
<48 hours after CT scan containing L3 area
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Fat free mass (kg), phase angle and impedance ratio measured by bioimpedance spectroscopy
Periodo de tiempo: <48 hours after CT scan containing L3 area
|
<48 hours after CT scan containing L3 area
|
|
Subjective assessment of muscle and fat wasting via SGA (normal, mild-moderate or severe)
Periodo de tiempo: <48 hours after CT scan containing L3 area
|
<48 hours after CT scan containing L3 area
|
|
Mid arm muscle circumference (cm)
Periodo de tiempo: <48 hours after CT scan containing L3 area
|
<48 hours after CT scan containing L3 area
|
|
Mean skeletal muscle mass measured by CT scan analysis at femoral area (cm2)
Periodo de tiempo: CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
|
Measured resting energy expenditure (kilojoules)
Periodo de tiempo: <48 hours after CT scan containing L3 area
|
<48 hours after CT scan containing L3 area
|
|
Intramuscular, subcutaneous and visceral adipose tissue CSA at L3 area (cm2)
Periodo de tiempo: CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Kate Lambell, MNutrDiet, La Trobe University and Alfred Health
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 523/16
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Observational cohort
-
Cairo UniversityTerminadoObesidad y Sobrepeso del SueñoEgipto
-
Centre Leon BerardNutricia, Inc.Aún no reclutandoTrastorno del olfato | Alteraciones del Gusto | Cambios en el Comportamiento AlimentarioFrancia
-
PeriPharmAún no reclutandoHidradenitis supurativa (HS)
-
PeriPharmAún no reclutandoEstudio en el Mundo Real sobre el Impacto de la Dermatitis Atópica desde la Perspectiva del CuidadorEczema | Dermatitis atópica | Cuidador | Carga | Eccema Dermatitis atópica
-
PeriPharmTerminadoLupus | Artritis lúpica | Artritis lúpica, lupus eritematoso sistémico | Calidad de vida (CV)Canadá
-
London Health Sciences Centre Research Institute...Activo, no reclutando
-
Bai-Rong XiaReclutamiento
-
Novartis PharmaceuticalsTerminadoTrasplante de riñónEstados Unidos, Hungría, Reino Unido, Bélgica, Países Bajos, Alemania, Australia, Francia, España, Suiza, Noruega, Letonia, Suecia, Japón, Argentina, Canadá, Italia, Corea del Sur, Brasil, Chequia